Cargando…

Corrigendum to: Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Corrigendum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9123234/ https://www.ncbi.nlm.nih.gov/pubmed/35023545 http://dx.doi.org/10.1093/eurheartj/ehab886

Ejemplares similares

Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis
por: Agarwal, Rajiv, et al.
Publicado: (2021)

Finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a FIDELITY analysis
por: Filippatos, Gerasimos, et al.
Publicado: (2023)

Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes
por: Filippatos, Gerasimos, et al.
Publicado: (2020)

Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium–Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis
por: Rossing, Peter, et al.
Publicado: (2022)

Corrigendum: Diabetes: how to manage chronic kidney disease
Publicado: (2022)

Finerenone efficacy in patients with chronic kidney disease, type 2 diabetes and atherosclerotic cardiovascular disease
por: Filippatos, Gerasimos, et al.
Publicado: (2022)

Finerenone for chronic kidney disease associated with type 2 diabetes with albuminuria
Publicado: (2023)

Modifiability of Composite Cardiovascular Risk Associated With Chronic Kidney Disease in Type 2 Diabetes With Finerenone
por: Agarwal, Rajiv, et al.
Publicado: (2023)

Blood Pressure and Cardiorenal Outcomes With Finerenone in Chronic Kidney Disease in Type 2 Diabetes
por: Ruilope, Luis M., et al.
Publicado: (2022)

Association of Finerenone Use With Reduction in Treatment-Emergent Pneumonia and COVID-19 Adverse Events Among Patients With Type 2 Diabetes and Chronic Kidney Disease: A FIDELITY Pooled Secondary Analysis
por: Pitt, Bertram, et al.
Publicado: (2022)

Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes
por: Agarwal, Rajiv, et al.
Publicado: (2023)

Pharmacotherapy considerations with finerenone in the treatment of chronic kidney disease associated with type 2 diabetes
por: Ashjian, Emily, et al.
Publicado: (2023)

Cost-effectiveness of finerenone in chronic kidney disease associated with type 2 diabetes in The Netherlands
por: Quist, Sara W., et al.
Publicado: (2023)

Corrigendum to “Urinary Exosomal MicroRNA Profiling in Incipient Type 2 Diabetic Kidney Disease”
por: Xie, Yijun, et al.
Publicado: (2018)

Kidney outcomes with finerenone: an analysis from the FIGARO-DKD study
por: Ruilope, Luis M, et al.
Publicado: (2022)

Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone
por: Agarwal, Rajiv, et al.
Publicado: (2020)

Modifying chronic kidney disease progression with the mineralocorticoid receptor antagonist finerenone in patients with type 2 diabetes
por: DeFronzo, Ralph A., et al.
Publicado: (2022)

Single institution prescribing pattern of finerenone in patients with type 2 diabetes and/or chronic kidney disease in the USA
por: Zhang, Rong M
Publicado: (2023)

A Systematic Review and Meta-Analysis on the Efficacy and Safety of Finerenone Therapy in Patients with Cardiovascular and Chronic Kidney Diseases in Type 2 Diabetes Mellitus
por: Jyotsna, FNU, et al.
Publicado: (2023)

Finerenone in Hispanic Patients With CKD and Type 2 Diabetes: A Post Hoc FIDELITY Analysis
por: Rosas, Sylvia E., et al.
Publicado: (2023)

Efficacy and safety of finerenone in chronic kidney disease and type 2 diabetes patients: a systematic review and meta-analysis
por: Yasmin, Farah, et al.
Publicado: (2023)

Renal Protection of Mineralocorticoid Receptor Antagonist, Finerenone, in Diabetic Kidney Disease
por: Kim, Dong-Lim, et al.
Publicado: (2023)

Corrigendum to “Endoplasmic reticulum stress is activated in post-ischemic kidneys to promote chronic kidney disease” [EBioMedicine 37 (2018) 269–280]
por: Shu, Shaoqun, et al.
Publicado: (2021)

Corrigendum to “A Case of Severe Acute Kidney Injury Exacerbated by Canagliflozin in a Patient with Type 2 Diabetes”
por: Hassani-Ardakani, Kimya, et al.
Publicado: (2021)

Network Meta-Analysis on the Effects of SGLT2 Inhibitors Versus Finerenone on Cardiorenal Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease
por: Zhao, Li-Min, et al.
Publicado: (2022)

CORRIGENDUM: N-Terminal Pro-B-Type Natriuretic Peptide Is a Predictor of Chronic Kidney Disease in an Asian General Population　― The Ohasama Study ―
por: Nakayama, Shingo, et al.
Publicado: (2020)

Cardiorenal benefits of finerenone: protecting kidney and heart
por: González-Juanatey, José R., et al.
Publicado: (2023)

Role of Finerenone in the Treatment of Diabetic Kidney Disease: Patient Selection and Clinical Perspectives
por: Shaikh, Aisha, et al.
Publicado: (2022)

Corrigendum to “An Emerging Translational Model to Screen Potential Medicinal Plants for Nephrolithiasis, an Independent Risk Factor for Chronic Kidney Disease”
por: Wu, San-Yuan, et al.
Publicado: (2015)

Corrigendum to “Prevalence of APOL1 Risk Variants in Afro-Descendant Patients with Chronic Kidney Disease in a Latin American Country”
por: Duran, Carlos E., et al.
Publicado: (2020)

Corrigendum to “Cordyceps militaris Improves Chronic Kidney Disease by Affecting TLR4/NF-κB Redox Signaling Pathway”
por: Sun, Tingli, et al.
Publicado: (2020)

Quality of Evidence Supporting the Role of Tripterygium Glycosides for the Treatment of Diabetic Kidney Disease: An Overview of Systematic Reviews and Meta-Analyses [Corrigendum]
Publicado: (2022)

Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease
por: Zhang, Yaofu, et al.
Publicado: (2022)

Corrigendum to: Proprotein convertase subtilisin/kexin type 9: an update on the cardiovascular outcome studies
Publicado: (2021)

Corrigendum to: Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-Pooled
Publicado: (2022)

Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO‐DKD trial
por: Filippatos, Gerasimos, et al.
Publicado: (2022)

Corrigendum to“Resistive index as a predictor of early failure of kidney transplantation”
por: Jeong, Dai Sik, et al.
Publicado: (2019)

Finerenone in patients across the spectrum of chronic kidney disease and type 2 diabetes by glucagon‐like peptide‐1 receptor agonist use
por: Rossing, Peter, et al.
Publicado: (2022)

Effects of Finerenone on Cardiovascular and Chronic Kidney Diseases: A New Weapon against Cardiorenal Morbidity and Mortality—A Comprehensive Review
por: Piccirillo, Francesco, et al.
Publicado: (2023)

Comparison of Respiratory Variations of Subclavian Vein and Inferior Vena Cava in Hospitalized Patients with Kidney Disease [Corrigendum]
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_uimuh15m2dakun5esko4qgcg2d